×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARDX – ardelyx, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/2
09:44 am
ardx
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results [Yahoo! Finance]
Low
Report
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results [Yahoo! Finance]
1/29
10:59 am
ardx
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/29
08:03 am
ardx
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $17.00 price target on the stock.
Low
Report
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $17.00 price target on the stock.
1/28
07:02 pm
ardx
Is Ardelyx (ARDX) Pricing Reflect Its Strong Multi Year Share Price Performance [Yahoo! Finance]
Low
Report
Is Ardelyx (ARDX) Pricing Reflect Its Strong Multi Year Share Price Performance [Yahoo! Finance]
1/28
12:37 pm
ardx
How Ardelyx's Phase 3 ACCEL Trial for IBSRELA in CIC Will Impact Ardelyx (ARDX) Investors [Yahoo! Finance]
Low
Report
How Ardelyx's Phase 3 ACCEL Trial for IBSRELA in CIC Will Impact Ardelyx (ARDX) Investors [Yahoo! Finance]
1/28
08:29 am
ardx
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Low
Report
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
1/27
07:19 am
ardx
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/26
10:16 am
ardx
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Low
Report
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
01:30 pm
ardx
Form SCHEDULE 13G/A ARDELYX, INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ARDELYX, INC. Filed by: VANGUARD GROUP INC
1/27
04:14 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Reilly Joseph James
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Reilly Joseph James
1/26
04:30 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Kelliher Mike
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Kelliher Mike
1/26
04:28 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Hohenleitner Susan
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Hohenleitner Susan
1/26
04:27 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Foster Eric Duane
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Foster Eric Duane
1/26
04:26 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: RAAB MICHAEL
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: RAAB MICHAEL
1/26
04:25 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Brady James Parker
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Brady James Parker
1/26
04:23 pm
ardx
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Williams Laura A
Low
Report
Form 4 ARDELYX, INC. For: Jan 23 Filed by: Williams Laura A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/2
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
71.2%
11/25 Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements 18.2%
12/3 UPDATE 1-Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study [Yahoo! Finance News] 16.8%
3/16 Form 4 ARDELYX, INC. For: Mar 12 Filed by: Cadoret-Manier Onaiza 13.9%
9/6 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. 13.3%
12/4 Ardelyx launches $80M stock offering; shares down 1% after hours [Seeking Alpha] 11.5%
2/14 Form SC 13G ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P. 10.6%
9/12 Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation 9.2%
10/10 Ardelyx to Host Analyst Day in New York 8.9%
8/20 Form 4 ARDELYX, INC. For: Aug 19 Filed by: GRAMMER ELIZABETH A 8.9%
11/25 Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements 18.2%
12/3 UPDATE 1-Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study [Yahoo! Finance News] 16.8%
3/16 Form 4 ARDELYX, INC. For: Mar 12 Filed by: Cadoret-Manier Onaiza 13.9%
9/6 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. 13.3%
12/4 Ardelyx launches $80M stock offering; shares down 1% after hours [Seeking Alpha] 11.5%
2/14 Form SC 13G ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P. 10.6%
9/12 Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation 9.2%
10/10 Ardelyx to Host Analyst Day in New York 8.9%
8/20 Form 4 ARDELYX, INC. For: Aug 19 Filed by: GRAMMER ELIZABETH A 8.9%
TOP News Decliners
12/3
Form 8-K ARDELYX, INC. For: Dec 03
-15.8%
3/16 Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors -13.0%
2/20 Form 5 ARDELYX, INC. For: Sep 05 Filed by: Rosenbaum David P. -9.0%
3/17 Form 8-K ARDELYX, INC. For: Mar 12 -8.4%
2/24 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
1/24 Double Your Money with This Biotech [The Motley Fool] -7.9%
9/16 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -7.7%
2/13 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -6.8%
10/8 Form 4 ARDELYX, INC. For: Oct 07 Filed by: Kaufmann Mark -6.4%
6/14 Form 8-K ARDELYX, INC. For: Jun 13 -6.4%
3/16 Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors -13.0%
2/20 Form 5 ARDELYX, INC. For: Sep 05 Filed by: Rosenbaum David P. -9.0%
3/17 Form 8-K ARDELYX, INC. For: Mar 12 -8.4%
2/24 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
1/24 Double Your Money with This Biotech [The Motley Fool] -7.9%
9/16 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -7.7%
2/13 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -6.8%
10/8 Form 4 ARDELYX, INC. For: Oct 07 Filed by: Kaufmann Mark -6.4%
6/14 Form 8-K ARDELYX, INC. For: Jun 13 -6.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: